We characterized CHIP and TI-CH in 421 patients with early-stage non-small cell lung cancer (NSCLC) from the TRACERx study and 49,351 patients from the MSK-IMPACT pan-cancer cohort. Here, C4B is linked to non-small cell lung carcinoma.